Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. (MRVI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mrvi · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Maravai LifeSciences Holdings, Inc. (MRVI) measures how much investors pay for each dollar of the company's trailing earnings. MRVI's current PE ratio of N/A is calculated by dividing its stock price of $5.04 by its TTM earnings per share of -$0.71.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%26.4x
MedianQ3 · 75%35.3x
Max
At N/A, MRVI's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Maravai LifeSciences Holdings, Inc.You MRVI | $1.4B | N/A | — | -$0.71 |
 Bicara Therapeutics Inc. Common Stock BCAX | $1.1B | N/A | — | -$2.52 |
 Ginkgo Bioworks Holdings, Inc. DNA | $543M | N/A | — | -$5.64 |
 Iovance Biotherapeutics, Inc. IOVA | $1.5B | N/A | — | -$1.09 |
 Kura Oncology, Inc. KURA | $751M | N/A | — | -$3.18 |
 LENZ Therapeutics, Inc. LENZ | $220M | N/A | — | -$2.85 |
 Prime Medicine, Inc. PRME | $559M | N/A | — | -$1.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.90 | — | |
2024-12-31 FY2024 | — | $-1.05 | — | |
2023-12-31 FY2023 | — | $-0.90 | — | |
2022-12-31 FY2022 | 8.55x | $1.67 | -67.6% | |
2021-12-31 FY2021 | 26.42x | $1.59 | -25.1% | |
2020-12-31 FY2020 | 35.26x | $0.80 | — | |
2019-12-31 FY2019 | — | $-0.09 | — | |
2018-12-31 FY2018 | — | $-0.20 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Maravai LifeSciences Holdings, Inc. (MRVI) measures how much investors pay for each dollar of the company's trailing earnings. MRVI's current PE ratio of N/A is calculated by dividing its stock price of $5.04 by its TTM earnings per share of -$0.71.
Frequently asked questions
MRVI pe ratio · 6 questionsMRVI's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.04 and TTM EPS of -$0.71. Data sourced from Financial Modeling Prep via MRVI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Maravai LifeSciences Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08